Filing Flows › Teva Pharmaceutical Industries (TEVA) › Operating margin
Teva Pharmaceutical Industries (TEVA) operating margin by quarter
Teva Pharmaceutical Industries' operating margin was 16.2% in Q3 2026 (third quarter 2026), -0.1 pts from Q1 2026. Over the last 6 quarters it ranged from 6.4% (Q4 2025) to 19.7% (Q3 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 16.2% | -0.1 pts | -3.4 pts |
| Q1 2026 | 16.4% | +10.0 pts | +3.0 pts |
| Q4 2025 | 6.4% | -13.3 pts | — |
| Q3 2025 | 19.7% | +8.8 pts | — |
| Q2 2025 | 10.9% | -2.4 pts | — |
| Q1 2025 | 13.3% | — | — |
Q3 2026 at a glance
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
What is Teva Pharmaceutical Industries' operating margin?
Teva Pharmaceutical Industries' operating margin was 16.2% in Q3 2026 (third quarter 2026), -0.1 pts from Q1 2026.
How has Teva Pharmaceutical Industries' operating margin changed?
Over the last 6 quarters it ranged from 6.4% (Q4 2025) to 19.7% (Q3 2025).
Q3 2026 results → · How Teva Pharmaceutical Industries makes money →